MCK - McKesson Corporation
| Previous Close | 135.56 |
| Open | 135.37 |
| Bid | 136.75 x 800 |
| Ask | 136.78 x 800 |
| Day's Range | 134.54 - 136.93 |
| 52 Week Range | 106.11 - 160.87 |
| Volume | 735,194 |
| Avg. Volume | 1,816,423 |
| Market Cap | 26.251B |
| Beta (3Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings Date | Jan 30, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | 1.56 (1.16%) |
| Ex-Dividend Date | 2019-02-28 |
| 1y Target Est | 137.31 |
- Zacks•4 days ago
Is McKesson Corporation (MCK) a Great Stock for Value Investors?
Is McKesson Corporation (MCK) a great pick from the value investor's perspective right now? Read on to know more.
- CNBC•7 days ago
FDA issues warning letter to drug distributor McKesson for allegedly shipping 'illegitimate' opioid products
The Food and Drug Administration has sent a warning letter to major drug distributor McKesson. The FDA accuses McKesson of failing to identify, investigate and stop people from tampering with its opioid shipments. The Food and Drug Administration said Tuesday it has sent a warning letter to drug distributor McKessson MCK for allegedly shipping "illegitimate" opioid products and failing to properly handle and investigate the incidents.
- American City Business Journals•7 days ago
Bay Area fintech opens office in Texas
The company’s site selection for its first office outside California highlights how prized Bay Area tech companies are for economic development, even in some of the nation’s largest cities.
- Zacks•7 days ago
Cardinal Health Strong on Pharmaceutical, Competition Rife
Cardinal Health (CAH) is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019.
- Investopedia•11 days ago
The World's Top 10 Health Care Companies (UNH, MDT)
Discover the world's top 10 health care companies according to market capitalization, including a brief summary of each.
- GlobeNewswire•11 days ago
Recent Analysis Shows Amerco, McKesson, Ophthotech, IQVIA, Highwoods Properties, and ABM Industries Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Markit•11 days ago
See what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCKView full report here! Summary * Perception of the company's creditworthiness is negative but improving * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MCK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MCK. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MCK totaled $14.26 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator with a strengthening bias over the past 1-month. MCK credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•13 days ago
Here's Why You Should Invest in McKesson (MCK) Stock Now
McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.
- Zacks•15 days ago
MCK vs. ALGN: Which Stock Should Value Investors Buy Now?
MCK vs. ALGN: Which Stock Is the Better Value Option?
- Zacks•15 days ago
Are Investors Undervaluing McKesson (MCK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- MarketWatch•17 days ago
Drug distributors’ stocks are caught in the middle of the opioid epidemic
Of these deaths, 47,600 (67.8%) involved opioids and 17,000 involved prescription opioids (24% of total overdose deaths). According to the National Institute on Drug Abuse, in the late 1990s, pharmaceutical companies reassured the medical community that patients would not become addicted to prescription opioid pain relievers, and healthcare providers began to prescribe them at greater rates. Today pharma distributors are used as scapegoats for the opioid epidemic — not because they are guilty but because they have money and they are “drug distributors.” They are dragged through the same mud as were the tobacco companies and British Petroleum (after it spilled millions of gallons of oil into the Gulf of Mexico).
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of MCK earnings conference call or presentation 31-Jan-19 10:00pm GMT
Q3 2019 McKesson Corp Earnings Call
- Motley Fool•18 days ago
McKesson Deals With Flat Earnings
The drug distributor remains confident about the full fiscal year.
- Zacks•18 days ago
McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View
McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.
- Morningstar•18 days ago
Steady Top-Line Growth for McKesson
The wide-moat firm's core drug distribution business posted gains of 6% in results that were largely in line with expectations.
Motley Fool•18 days agoMcKesson (MCK) Q3 2019 Earnings Conference Call Transcript
MCK earnings call for the period ending December 31, 2018.
- Zacks•19 days ago
McKesson (MCK) Q3 Earnings and Revenues Beat Estimates
McKesson (MCK) delivered earnings and revenue surprises of 6.92% and 1.69%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- MarketWatch•19 days ago
McKesson stock ticks higher after earnings beat
McKesson Corp. shares ticked higher in the extended session Thursday after the health-care supply-chain management company's results topped Wall Street estimates. McKesson shares rose 0.6% after hours, following a 2.6% rise to close the regular session at $128.25. The company reported fiscal third-quarter net income of $469 million, or $2.40 a share, compared with $903 million, or $4.33 a share, in the year-ago period. Adjusted earnings were $3.40 a share. Revenue rose to $56.21 billion from $53.62 billion in the year-ago quarter. Analysts surveyed by FactSet had forecast earnings of $3.15 a share on revenue of $55.06 billion. For the year, McKesson narrowed its forecast adjusted earnings to a range of $13.45 to $13.65 from the previous range of $13.20 to $13.80 a share. Analysts had forecast earnings of $13.40.
- Associated Press•19 days ago
McKesson: Fiscal 3Q Earnings Snapshot
The San Francisco-based company said it had profit of $2.40 per share. Earnings, adjusted for one-time gains and costs, came to $3.40 per share. The results topped Wall Street expectations. The average ...
- Business Wire•19 days ago
McKesson Reports Fiscal 2019 Third-Quarter Results
SAN FRANCISCO-- -- Revenues of $56.2 billion for the third quarter, up 5% year over year. Third-quarter GAAP earnings per diluted share from continuing operations of $2.41. Third-quarter Adjusted Earnings per diluted share of $3.40, flat year over year. Fiscal 2019 Outlook: Adjusted Earnings of $13.45 to $13.65 per diluted share. McKesson Corporation today reported that revenues for the third quarter ...
- Moody's•20 days ago
Change Healthcare Holdings LLC -- Moody's downgrades Change Healthcare's CFR to B2, facility ratings to B1/Caa1; outlook stable
Rating Action: Moody's downgrades Change Healthcare's CFR to B2, facility ratings to B1/Caa1; outlook stable. Global Credit Research- 30 Jan 2019. Nearly $6.5 billion of rated debt affected.
- Zacks•20 days ago
Medical Products' Earnings Lineup for Jan 31: EW, BAX & More
Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.
- Zacks•22 days ago
Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?
McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.
- Barrons.com•22 days ago
The 15 Companies Least Vulnerable to Climate Change Risk
There is growing recognition of the risks that climate change poses to companies and their investors. But some companies don’t have nearly as much to worry about as others.
- CNBC Videos•11 days ago
Does FedEx look good here? What's the deal with McKesson? Buy Abbvie?
The "Halftime Report" traders take viewer questions on FedEx, McKesson, Abbvie, Foot Locker and Starbucks.
